ClinicalTrials.Veeva

Menu
O

Oakland Hills Dermatology | Auburn Hills, MI

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lebrikizumab
Rocatinlimab
Spesolimab
BIIB059
AMG 451
BI 655130
Upadacitinib
Ritlecitinib
DS-7011a
Dupilumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 17 total trials

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental viti...

Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo
Status recently updated

The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urtic...

Not yet enrolling
Enrolling
Chronic Spontaneous Urticaria
Biological: barzolvolimab
Biological: Matching placebo

The coprimary objectives of the study are to:* evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcin...

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

The primary objectives of this study are to:* estimate vaccine response in rocatinlimab group vs placebo group, assessed using antibody anti-tetanus...

Active, not recruiting
Atopic Dermatitis
Moderate-to-severe Atopic Dermatitis
Drug: Placebo
Drug: Rocatinlimab

The main purpose of this study is to determine the safety and efficacy lebrikizumab in adolescent and adult participants with moderate-to-severe atop...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab

Systemic lupus erythematosus (SLE) is a systemic chronic autoimmune disease characterized by autoantibody production, inflammation, and tissue damage...

Enrolling
Systemic Lupus Erythematosus
Drug: DS-7011a
Drug: Placebo

The study will assess the safety and efficacy of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD) pre...

Active, not recruiting
Atopic Dermatitis
Drug: Lebrikizumab

The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18...

Enrolling
Atopic Dermatitis
Eczema
Drug: Placebo
Drug: Lebrikizumab

Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to...

Invitation-only
Vitiligo
Drug: Placebo
Drug: Upadacitinib

The primary objectives of the study are to evaluate the efficacy of BIIB059 (litifilimab) compared with placebo in reducing skin disease activity mea...

Enrolling
Subacute Cutaneous Lupus Erythematosus
Chronic Cutaneous Lupus Erythematosus
Drug: BIIB059 (litifilimab)
Drug: Placebo

The main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with mode...

Enrolling
Atopic Dermatitis
Eczema
Drug: Lebrikizumab
Drug: Placebo
Locations recently updated

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent subje...

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

This study is open to people with generalized pustular psoriasis (GPP). People can only take part if they have completed treatment in a previous stud...

Active, not recruiting
Generalized Pustular Psoriasis
Drug: Spesolimab

Trial sponsors

Lilly logo
Amgen logo
AbbVie logo
Boehringer Ingelheim logo
A
Biogen logo
Celldex Therapeutics logo
Daiichi Sankyo logo
Janssen (J&J Innovative Medicine) logo
Pfizer logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems